title: TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
abstract: Immunotherapies that harness the activity of the immune system against tumors are proving to be an effective therapeutic approach in multiple malignancies. Indeed, through accumulation of genetic mutations, many tumors express antigens that can potentially elicit specific tumor immunity. However, tumors can also suppress these responses by activating negative regulatory pathways and checkpoints such as PD-1/PD-L1 and CTLA-4. Blocking these checkpoints on T cells has provided dramatic clinical benefit, but only a subset of patients exhibit clear and durable responses, suggesting that other mechanisms must be limiting the immune response. We discuss here the role of TIGIT, an inhibitory receptor expressed by lymphocytes, in limiting antitumor responses and we review its mechanisms of action during the cancer immunity cycle.
authors: Department of Cancer Immunology, Genentech, South San Francisco, CA, USA.
authors: Nicholas A
authors: NA
authors: Manieri
authors: Department of Cancer Immunology, Genentech, South San Francisco, CA, USA.
authors: Eugene Y
authors: EY
authors: Chiang
authors: Department of Cancer Immunology, Genentech, South San Francisco, CA, USA. Electronic address: grogan.jane@gene.com.
authors: Jane L
authors: JL
authors: Grogan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D011971:Receptors, Immunologic / Q000276:immunology / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061025:Costimulatory and Inhibitory T-Cell Receptors; D011971:Receptors, Immunologic; C534712:TIGIT protein, human